Core Viewpoint - The company is enhancing its AI medical model business through a strategic partnership with Shenzhen Computing Science Research Institute, focusing on high-quality medical data for training and application [1][2] Group 1: Partnership and Collaboration - The company’s subsidiary, Shenzhen Yishuzhengcheng Technology Co., Ltd., has signed an ecological cooperation agreement with Shenzhen Computing Science Research Institute [1] - The collaboration aims to leverage each party's resources, talent, and technological advantages in database, data quality, and data analysis [1][2] Group 2: AI Medical Model Development - The company is actively developing AI medical models, which require high-quality, secure, and available medical big data as core support [1] - Medical data includes diverse forms such as medical records, imaging, and test reports, necessitating precise data cleaning and annotation [1] Group 3: Strategic Goals - The board believes that the partnership will create a closed-loop ecosystem of "data governance + model iteration + scenario implementation" [2] - This integration will enable the company to provide comprehensive data services, including data cleaning, intelligent analysis, and customized model training for various clients [2] - High-quality data and precise analytical capabilities are expected to accelerate the optimization and commercialization of the company's AI medical models, enhancing its core competitiveness in the AI healthcare sector [2]

Core Viewpoint - The company has signed an ecological cooperation agreement with Shenzhen Computing Science Research Institute to enhance its AI medical model business through collaboration in data quality and analysis [1][2] Group 1: Strategic Cooperation - The agreement aims to leverage the advanced technologies developed by the Shenzhen Computing Science Research Institute in database systems, data quality systems, and data analysis systems [2] - The collaboration will create a closed-loop ecosystem of "data governance + model iteration + scenario implementation" [2] - This partnership is expected to provide comprehensive data services, including data cleaning, intelligent analysis, and customized model training for clients in the healthcare sector, government departments, and industry AI applications [2] Group 2: AI Medical Model Development - The company is focusing on the development of AI medical models, which require high-quality, secure, and available medical big data as core support [1] - The medical data encompasses various forms such as medical records, imaging, and laboratory reports, necessitating high precision in data cleaning and labeling [1] - The collaboration is anticipated to accelerate the optimization and commercialization of the company's AI medical models, enhancing its core competitiveness in the AI healthcare sector [2]

Core Viewpoint - The announcement highlights a strategic partnership between Teda Biomedical (08189.HK) and Shenzhen Institute of Computing Sciences, focusing on collaborative efforts in database development, data quality, and data analysis applications [1] Group 1 - Teda Biomedical's subsidiary, Shenzhen Yishuzhengcheng Technology Co., Ltd., has signed an ecological cooperation agreement with Shenzhen Institute of Computing Sciences [1] - The collaboration aims to leverage each party's resources, talent, and technological advantages [1] - The focus of the partnership will be on research and market applications related to databases, data quality, and data analysis value [1]

Core Viewpoint - The company has signed an ecological cooperation agreement with Shenzhen Computing Science Research Institute to enhance its AI medical model business through collaboration in data quality and analysis [1][2] Group 1: Strategic Partnership - The partnership aims to leverage each party's resources, talent, and technological advantages for deep cooperation in database, data quality, and data analysis [1] - The agreement will integrate cutting-edge technologies developed by the research institute in database systems, data quality systems, and data analysis systems [2] Group 2: AI Medical Model Development - The company is focusing on the development of AI medical models, which require high-quality, secure, and available medical big data as core support [1] - The collaboration will enable the company to provide a full-process service covering data cleaning, intelligent analysis, and customized model training for various clients, including medical institutions and government departments [2] Group 3: Competitive Advantage - By utilizing high-quality data and precise analytical capabilities, the company aims to accelerate the optimization and commercialization of its AI medical models [2] - This strategic move is expected to strengthen the company's core competitiveness in the AI medical sector [2]

本公告由天津泰達生物醫學工程股份有限公司（「本公司」，連同其附屬公司統稱「本集 團」）自願刊發，以向本公司股東及潛在投資者提供有關本集團的最新業務進度的信息。 簽署合作協議 本公司董事（「董事」）會（「董事會」）欣然宣佈，近期本集團附屬公司深圳醫數精誠科技 有限公司（「醫數精誠」）與深圳計算科學研究院（「深算院」）簽署生態合作協議。雙方充 分發揮各自資源、人才和技術優勢，共同在數據庫、數據質量和數據分析價值方面的研 發和市場應用形成深度合作。 1 香港聯合交易所有限公司對本公佈之內容概不負責，對其準確性或完整性亦不發表任 何聲明，並明確表示概不就因本公佈全部或任何部分內容而產生或因倚賴該等內容而 引致之任何損失承擔任何責任。 天津泰達生物醫學工程股份有限公司 Tianjin TEDA Biomedical Engineering Company Limited （於中華人民共和國註冊成立的股份有限公 司） （股份代 號：8189） 自願公告 簽署生態合作協議 有關深算院的資料 深算院是深圳市人民政府2018年11月批准建設的「十大基礎研究機構」之一，由深圳市 科技創新委員會主管，深圳大學舉辦，深圳市龍華區人民 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年7月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 天津泰达生物医学工程股份有限公司 呈交日期: 2025年8月4日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 08189 | 說明 | H股 | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 1,436,400,000 | RMB | | 0.1 RMB | | 143,640,000 | | 增加 / 減少 (-) | | | | | | RMB | | | | 本月底結存 | | | 1,436,400,000 | RMB | | 0.1 RMB | | 143,640,000 | | 2. 股份分類 | 普通股 | 股份類 ...

Core Viewpoint - The strategic cooperation agreement between Beijing Boya Quanjian Intelligent Technology Co., Ltd. and China Telecom's Ningxia branch aims to leverage each other's strengths in resources, talent, and technology to enhance the application of big data in healthcare and artificial intelligence [1] Group 1: Strategic Cooperation - The agreement will establish a long-term strategic partnership focusing on medical health big data applications and AI implementation [1] - The collaboration will utilize China Telecom's robust network resources and data advantages in Ningxia, while Boya Quanjian will contribute its expertise in AI and healthcare technology [1] - This partnership is expected to accelerate the development of AI healthcare technologies and enhance the company's competitive edge in the "AI + healthcare" sector [1] Group 2: Operational Framework - Boya Quanjian has developed a full-chain operational system that integrates technology research and development, scenario implementation, and industry empowerment [2] - The company collaborates with hospitals affiliated with Peking University to utilize data from various medical fields to create tailored AI models for specific applications [2] - An open collaborative ecosystem is being built to enhance technology transfer and implementation efficiency in areas like AI-assisted diagnosis [2]

Financial Performance - For the fiscal year ending December 31, 2023, the company's revenue was RMB 397,998,000, a decrease of 1.8% compared to RMB 403,729,000 in 2022[11] - The gross profit for the same period was RMB 21,366,000, resulting in a gross margin of 5.37%, slightly down from 5.25% in 2024[11] - The company reported a loss attributable to shareholders of RMB 20,160,000, which is an improvement from a loss of RMB 27,452,000 in 2022[11] - Total assets as of December 31, 2023, were RMB 303,278,000, while total liabilities increased to RMB 238,699,000[11] - The total revenue for the year ended December 31, 2024, was RMB 385,482,322, a decrease of 3.14% compared to RMB 397,998,097 in 2023[43] - The comprehensive gross profit for the year was RMB 20,222,876, with a gross margin of 5.25%, down from 5.37% in the previous year[43] - The group reported a loss attributable to owners of RMB 27,802,241 for the year ended December 31, 2024, compared to a loss of RMB 20,159,658 for the year ended December 31, 2023, with a loss per share of RMB 1.46[50] Business Operations - The company operates in two main business areas: bio-composite fertilizers and elderly care services, with ongoing efforts in both sectors[7] - The company plans to expand its elderly care services and integrate management operations across the nation[7] - The gross profit margin for the bio-composite fertilizer segment has shown fluctuations, indicating potential areas for operational improvement[11] - The company established an e-commerce sales platform to expand market coverage and introduced new products such as liquid fertilizers and water-soluble compound fertilizers[17] - The company aims to enhance market marketing management and adjust product structure to improve market share in the compound fertilizer sector[23] - The company has expanded its product offerings to include liquid fertilizers and water-soluble compound fertilizers to meet market demand[34] Research and Development - The company is committed to enhancing its research and development capabilities in both fertilizer and healthcare sectors[7] - The company is actively developing new environmentally friendly fertilizer products in response to increasing quality demands from farmers[30] - The company is committed to integrating advanced technologies into its healthcare services to accelerate digital and intelligent upgrades in the elderly care sector[24] Market Trends - In 2024, the compound fertilizer market experienced structural adjustments, with nitrogen fertilizer prices fluctuating at low levels due to capacity release, while phosphate fertilizer remained high due to resource costs[16] - The national food production target is set to stabilize above 1.3 trillion jin, which is expected to drive rigid growth in fertilizer demand[17] - The fertilizer industry has improved its supply-demand balance and industry concentration due to structural reforms and stricter environmental policies[64] Corporate Governance - The company has appointed independent non-executive directors with extensive experience in accounting and law, enhancing governance and oversight[94][95][96] - The company is committed to ensuring compliance with its articles of association regarding board and supervisory board member requirements[87] - The board is led by Chairwoman Sun Li, who is responsible for the company's development strategy and risk management[126] - The company will seek to enhance corporate governance transparency and independence in the near future[129] Environmental Responsibility - The company maintains a corporate social responsibility strategy focused on employee care, environmental protection, and social responsibility[162] - The company adheres to strict environmental regulations, ensuring that emissions meet national standards[165] - Waste management practices include comprehensive utilization of solid waste, with all solid waste being recycled[165] - The company has implemented energy-saving measures and pollution control technologies in its operations[163] Financial Management - The audit committee held two meetings during the fiscal year and reviewed the financial reporting procedures of the group[117] - The financial statements for the year ending December 31, 2024, were audited by Fan Chen CPA Limited[121] - The company has provisions for shareholders to convene a special general meeting if they hold at least 10% of the issued share capital[157] - The total remuneration for executive director Sun Li for the fiscal year 2024 was RMB 516,303, a decrease of 16.7% from RMB 620,127 in 2023[153] Shareholder Engagement - The company emphasizes high transparency and timely disclosure of relevant information to shareholders[160] - The company encourages shareholder participation in annual general meetings, providing opportunities for direct dialogue[160]

Financial Performance - For the fiscal year ending December 31, 2024, the company reported a revenue of RMB 385,482,000, a decrease of 3.8% from RMB 397,998,000 in 2023[3] - The gross profit for 2024 was RMB 20,223,000, representing a gross margin of 5.25%, slightly down from 5.37% in 2023[3] - The net loss attributable to shareholders for 2024 was RMB 27,802,000, compared to a loss of RMB 20,160,000 in 2023, indicating a worsening financial performance[3] - The company reported a basic and diluted loss per share of RMB 1.46 for 2024, compared to RMB 1.06 in 2023, indicating a decline in shareholder value[6] - The company reported a total comprehensive loss of RMB 27,802,241 for the year ended December 31, 2024[12] - The company reported a loss attributable to owners of RMB (27,802,241) in 2024, compared to a loss of RMB (20,159,658) in 2023, indicating a significant increase in losses[40] - The group reported a loss attributable to owners of RMB 27,802,241 for the year ended December 31, 2024, compared to RMB 20,159,658 in 2023, with a loss per share of RMB 1.46, up from RMB 1.06[76] Assets and Liabilities - Total assets as of December 31, 2024, amounted to RMB 332,527,000, an increase from RMB 303,278,000 in 2023[3] - Total liabilities increased to RMB 304,087,000 in 2024 from RMB 238,699,000 in 2023, reflecting a significant rise in financial obligations[3] - The company’s non-current assets decreased to RMB 98,533,261 in 2024 from RMB 112,936,039 in 2023, reflecting a reduction in long-term investments[7] - Total equity attributable to shareholders dropped to RMB 22,149,067 in 2024 from RMB 49,951,308 in 2023, highlighting a significant decline in shareholder equity[8] - The group’s asset-liability ratio was 0.91 as of December 31, 2024, compared to 0.79 in 2023, indicating an increase in financial leverage[83] Cash Flow and Liquidity - The company’s cash and cash equivalents rose to RMB 25,399,950 in 2024, up from RMB 5,934,322 in 2023, indicating improved liquidity[7] - As of December 31, 2024, the company's current liabilities were approximately RMB 279,065,167, while cash and cash equivalents stood at only RMB 25,399,950, resulting in a net current liability position of RMB 45,071,379[53] - The company incurred total employee costs of RMB 27,726,792 in 2024, up from RMB 24,361,521 in 2023[36] Revenue Breakdown - Revenue from fertilizer products was RMB 384,846,908, down from RMB 397,424,063 in the previous year, indicating a decline of 3.1%[14] - The revenue from the sale of general fertilizers was RMB 359,752,928 in 2024, down from RMB 378,821,948 in 2023, representing a decline of about 5.0%[28] - Revenue from external customers for the year ended December 31, 2024, was RMB 385,482,322, a decrease from RMB 397,998,097 in 2023, representing a decline of approximately 3.8%[22][23] Research and Development - Research and development expenses for 2024 were RMB 1,102,139, a decrease from RMB 1,319,315 in 2023, suggesting a potential shift in focus or cost management[6] - Research and development expenses were RMB 1,102,139, a decrease of 16.46% from RMB 1,319,315 in the previous year, reflecting the R&D spending of the high-tech enterprise Guangdong Fuli Long[73] Strategic Moves - The company sold 82.76% of its stake in Shanghai Weidi Network Technology Co., Ltd., marking a strategic exit from the health products segment[18] - The company has classified Shanghai Weidi as a disposal group held for sale, terminating the operation of its "health products (alcohol) and related services" business[31] - The company plans to enhance product quality and develop new environmentally friendly fertilizers in response to increasing demands for fertilizer effectiveness and environmental regulations[59] Market and Industry Outlook - The composite fertilizer market experienced structural adjustments in 2024, with nitrogen fertilizer prices fluctuating at low levels and phosphate prices supported by resource costs[59] - The demand for composite fertilizers is expected to grow due to government policies aimed at stabilizing grain production above 1.3 trillion jin, enhancing farmers' planting enthusiasm[59] Shareholder Information - Major shareholders include state-owned assets management with 182,500,000 shares (9.63%), and Xiangyong Investment with 180,000,000 shares (9.50%) as of December 31, 2024[95] - The company has not declared or paid any dividends in both 2023 and 2024[39] Compliance and Governance - The company has complied with all provisions of the Corporate Governance Code except for A.2.1 during the review year, emphasizing effective board structure and transparency to shareholders[104] - The audit committee was established in accordance with GEM listing rules and consists of three independent non-executive directors, with a focus on financial reporting and internal controls[103]

Financial Performance - For the six months ended June 30, 2024, the group achieved a consolidated revenue of RMB 211,568,049, representing a year-on-year growth of 16.24% compared to RMB 185,915,928 for the same period in 2023[2] - The consolidated gross profit for the same period was RMB 12,115,570, reflecting a significant year-on-year increase of 76.90% from RMB 6,848,825 in 2023[2] - The loss attributable to equity holders of the company for the six months ended June 30, 2024, was RMB 4,123,183, a reduction from a loss of RMB 11,250,040 in the same period of 2023[3] - The basic loss per share for the period was RMB 0.218, improved from RMB 0.594 per share in the previous year[3] - Revenue from fertilizer products and elderly care services reached RMB 211,314,827 for the six months ended June 30, 2024, up from RMB 181,559,688 in 2023, indicating a growth of approximately 16.4%[9] - The company reported a basic loss per share of RMB (4,123,183) for the six months ended June 30, 2024, compared to RMB (11,250,040) in 2023, showing an improvement in loss[14] Assets and Liabilities - The total assets as of June 30, 2024, amounted to RMB 310,052,847, compared to RMB 303,277,966 as of December 31, 2023[4] - Current assets totaled RMB 200,402,798 as of June 30, 2024, an increase from RMB 190,341,927 at the end of 2023[4] - Current liabilities were RMB 224,172,039 as of June 30, 2024, compared to RMB 216,842,145 at the end of 2023[5] - Non-current assets were valued at RMB 109,650,049 as of June 30, 2024, down from RMB 112,936,039 at the end of 2023[4] - The total asset value of the group was approximately RMB 310,052,847 as of June 30, 2024, compared to RMB 303,277,966 as of December 31, 2023, with total liabilities of RMB 224,172,039[33] - The company's debt-to-asset ratio increased to 0.81 as of June 30, 2024, from 0.79 as of December 31, 2023, while the capital debt ratio rose to 0.30 from 0.22[33] Cash Flow and Financing - Cash and bank balances increased to RMB 18,199,595 as of June 30, 2024, from RMB 5,934,322 at the end of 2023[4] - The company reported a net cash flow from operating activities of RMB 8,044,015 for the six months ended June 30, 2024, compared to RMB 1,915,186 for the same period in 2023, representing a significant increase[6] - The company incurred financing expenses of RMB 1,977,660 for the six months ended June 30, 2024, compared to RMB 1,521,452 in 2023, reflecting an increase of about 30%[10] - The company had a financing cash flow net amount of RMB 4,970,000 for the six months ended June 30, 2024, compared to no financing cash flow in the same period of 2023[6] - The company did not incur any income tax expenses for the six months ended June 30, 2024, compared to RMB (41) in 2023, indicating a tax relief situation[12] Operational Highlights - The company has strengthened market sales management and adjusted product structure based on market demand, leading to steady progress in the compound fertilizer business[26] - The company is actively developing elderly health resource allocation services, including the rental of assistive devices and the sale of elderly food products[28] - The company has reserved a large amount of low-cost raw materials to ensure profit margins amid market price fluctuations[28] - The company is focused on providing management consulting services to other elderly care institutions and plans to build its own elderly care facilities when appropriate[27] - The aging population in China, with 300 million people aged 60 and above, presents a significant opportunity for the company to expand its elderly care services and related businesses[38] - The company is focusing on developing elderly health resource allocation services, including rental of assistive devices and sales of elderly food products, with plans to expand into more categories[38] Shareholder Information - As of June 30, 2024, Tianjin Economic and Technological Development Zone State-owned Assets Management Co., Ltd. holds 182,500,000 shares, representing 9.63% of the total share capital[43] - Guangdong Jiamei Ecological Technology Co., Ltd. owns 180,000,000 shares, accounting for 9.50% of the total share capital[43] - Green Field Fertilizer holds 120,000,000 shares, which is 6.33% of the total share capital[43] - The company did not declare any interim dividend for the six months ended June 30, 2024[52] - No new share option schemes were approved during the period ending June 30, 2024[47] - The company did not repurchase any of its shares during the review period[50] Governance and Compliance - The audit committee consists of three independent non-executive directors, ensuring effective communication regarding financial reporting[46] - The company has complied with all provisions of the corporate governance code except for the separation of the roles of chairman and CEO[51] - There were no management contracts signed for overall business or any major business operations during the first half of 2024[48] - The board of directors has not been aware of any other individuals holding 5% or more of the issued share capital during the review period[44] Market Risks - The company faces minimal foreign currency risk as all sales and payments to suppliers are settled in RMB[35] - The company's liquidity ratio was 0.89 as of June 30, 2024, slightly up from 0.88 as of December 31, 2023[33]